Adis Journals
Tapinarof cream 1% Adis Drug Q&A Summary slide - UPDATED.pdf (223.2 kB)

Tapinarof cream 1% in plaque psoriasis: a profile of its use

Download (223.2 kB)
online resource
posted on 2023-07-26, 22:27 authored by Matt Shirley



Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest M. Shirley is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here.


 Tapinarof (VTAMA®) cream 1%, a topical, non-steroidal, aryl hydrocarbon receptor agonist, presents a valuable addition to the therapy options for topical treatment of plaque psoriasis in adults. In the pivotal 12-week, randomized, double-blind, vehicle-controlled, phase 3 PSOARING 1 and PSOARING 2 trials, once-daily tapinarof cream 1% was shown to be efficacious in reducing the severity of plaque psoriasis. Furthermore, evidence from an open-label extension study shows that continuous and intermittent use of tapinarof cream 1% for up to 1 year has durable on-treatment efficacy with a substantial remittive effect off treatment. Tapinarof cream 1% was generally well tolerated, with few patients discontinuing treatment in the pivotal trials due to adverse events, and with no new safety signals identified with longer-term treatment. Post-marketing real-world data and/or active-controlled studies to compare tapinarof cream 1% with other topical treatments used for plaque psoriasis would be of interest. 


© Springer Nature Switzerland AG 2023


Usage metrics

    Drugs & Therapy Perspectives



    Ref. manager